PF-Atlas › Clinical Trials › NCT02722122

Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®

AIR DNase™ · Phase 2

Registry ID

NCT02722122

Phase

Phase 2

Status

Unknown

Drug / intervention

AIR DNase™

Sponsor

Protalix

Start

2016-05

About this trial

AIR DNase™ is evaluated in NCT02722122, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Protalix. Current status: Unknown.

View NCT02722122 on ClinicalTrials.gov →

Explore related

All AIR DNase™ trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT02722122 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.